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ANALGESIC EFFICACY OF CR4056, A NOVEL I2-IMIDAZOLINE
RECEPTOR LIGAND, IN THE RAT MONOSODIUM IODOACETATE
MODEL OF OSTEOARTHRITIC PAIN
G. Caselli y, E. Comi y,z, F. Ferrari y, V. Mauri y, L. Catapano y, M. Lanza y,
M. Lanza y, L.C. Rovati y. yRottapharm Biotech Srl, Monza, Italy; zUniv. of
Milan-Bicocca, Monza, Italy
Purpose: Joint pain is the earliest symptom of osteoarthritis (OA)
although clinical data suggest that it poorly correlates with OA radio-
logical features. Interestingly, recent studies show that OA pain is driven
by both nociceptive and neuropathic mechanisms. CR4056 is a prom-
ising analgesic drug that binds to imidazoline-2 receptors and that was
previously reported to be effective in several animal models of
inﬂammatory, neuropathic, and postoperative pain. The aim of this
study was to evaluate the effect of CR4056 in a well-established model
of OA pain mimicking the painful components of human OA. The model
consisted in the injection of monosodium iodoacetate (MIA) into the
knee joint of rats, which produces cartilage degeneration and pain.
Methods:Unilateral painwas induced by a single intra-articular injection
of 1mg/50ml MIA in the infrapatellar area of the right knee of maleWistar
rats (6 animals/group). Pain thresholds were determined as mechanical
allodynia (Dynamic Plantar Aesthesiometer- electronic Von Frey test) and
mechanical hyperalgesia (Pressure Application Measurement - PAM
device) on day 1 before MIA injection, and on day 7, 14 and 21 after MIA
injection. CR4056 (2, 6 mg/kg) or 10 mg/kg naproxen were administered
orally, as single treatment on day 7 post injury and from day 14 to day 21,
once daily, as sub-chronic treatments. Statistical analysis was performed
byTwo-wayRMANOVA, followedbyDunnett'smultiplecomparisons test.
Results: Intra-articular injection of MIA induced both mechanical allo-
dynia of the ipsilateral paw and mechanical hyperalgesia of the ipsi-
lateral knee, either comparedwith the contralateral pawand knee or the
saline control. Since 7 days after the inductionwithMIA the difference of
pain behaviour between sham and arthritic rats was highly statisticallysigniﬁcant both for allodynia (mean± sem, 36.4± 0.82 g vs. 26.5± 0.98 g,
respectively) and for hyperalgesia (1086 ±13.3 g vs. 692 ± 26.6 g,
respectively). The difference between sham and MIA rats remained
constant throughout the study. Acute oral administration of CR4056, 7
days after MIA, induced a dose-dependent reversal of MIA induced pain
behaviours evaluated 90 minutes after treatment, that attained stat-
istical signiﬁcance (p<0.05) for the 6 mg/kg dose (40% and 33% reversal
for allodynia and hyperalgesia, respectively). Naproxen at 10 mg/kg
produced a lower and non-signiﬁcant analgesia. Even more interest-
ingly, as illustrated in the Figure, subacute treatment from days 14 to 21
after MIA with CR4056 (both doses) and naproxen, showed statistically
signiﬁcant anti-hyperalgesic effects (90’ after treatment). Subacute 10
mg/kg Naproxen and 6 mg/kg CR4056 were also signiﬁcantly effective
against allodynia. Moreover, the rats treated for 7 days with 6 mg/kg
CR4056 showed a signiﬁcant reduction of both basal pain behaviours
(allodynia and hyperalgesia), demonstrating either a long lasting effect
or, even, a true symptommodifying effect. A similar effect was observed
after naproxen, but this was only limited to hyperalgesia.
Conclusions: The data here presented show that the imidazoline I2 ligand
CR4056 could represent a new highly effective treatment option for OA pain
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SUBSTANCE P EXPRESSION IN THE MURINE LUMBAR DORSAL ROOT
GANGLIA: EFFECT OF CHRONIC INFLAMMATORY ARTHRITIS KNEE
PAIN AND TREATMENT WITH IA VANILLOIDS
H.E. Krug y,z, J.S. Bert y, C.W. Dorman z, S.P. Frizelle z,
S.C. Funkenbusch z, M.L. Mahowald y,z. yUniv. of Minnesota, Minneapolis,
MN, USA; zVA Hlth.Care System, Minneapolis, MN, USA
Purpose: Capsaicin (CAP) and Resiniferatoxin (RTX) are vanilloid
receptor agonists that when given by intra-articular (IA) injections, can
normalize Evoked Pain Scores (EPS) and Automated Dynamic Weight
Bearing (ADWB) measures in carrageenan-induced acute inﬂammatory
arthritis. To determine whether these vanilloid receptor agonists might
have beneﬁt in chronic inﬂammatory arthritis pain, we measured
changes in ADWB and EPS due to joint pain in mice with Complete
Freund’s Adjuvant (CFA) induced chronic inﬂammatory arthritis with
and without treatment with IA injections of CAP and RTX.
Methods: Chronic Inﬂammatory arthritis was produced by IA injection
of 30 ml of CFA into the left knee of C57BL6 male mice 3 weeks prior to
pain behavior testing. Mice were injected with IA RTX (10ml of 0.001%)
or 10ml of 0.01% IA CAP 7 days prior to measurement of EPS and ADWB.
Evoked pain behavior was measured by tallying ﬁghts and vocalizations
per one minute with repeated palpation of the knee at 15.6 psi. ADWB
(%weight on each limb and %time on each limb) was measured using an
Automated Dynamic Weight Bearing apparatus (Bioseb, Vitrolles,
France). Following pain behavior testing, animals were euthanized with
CO2 and L2-5 dorsal root ganglia (DRG) were harvested from ipsilateral
and contralateral sides after perfusion with 4% paraformaldehyde. Forty
micron sections were incubated with primary anti-SP followed by ﬂu-
orescent secondary antibody. DRG neurons expressing SP were counted
manually after imaging with confocal ﬂuorescent microscopy as a
proportion of total DRG neurons.
Results: Chronic inﬂammatory arthritis induced by IA CFA resulted in a
signiﬁcantly increased EPS (3.5) and a decrease in left to right ADWB
ratios for weight (0.76) and time (0.93) when compared with naïve
controls. Treatment with IA CAP 7 days prior to pain behavior testing
resulted in minimal improvement in EPS (2.94) and no improvement of
left to right ADWB ratios for weight (0.72) or time (0.83) when com-
pared to the chronic inﬂammatory arthritis model. Treatment with IA
0.001% RTX 7 days prior to the exam led to improved EPS (1.71) and
improved left to right ADWB ratios for weight (0.88) but no change in
time (0.95) when compared to the chronic inﬂammatory arthritis
model, but these improvements were not statistically signiﬁcant. IA
injection of CAP and RTX into naïve knees produced no increase in EPS
or decrease in ADWBmeasures. DRG staining for SP showed an increase
in the percent neurons expressing SP after development of arthritis
from 16.7 to 31.2%. Pretreatment with CAP reduced this to nearly nor-
mal (21%) in spite of the lack of analgesic effect. Treatment with CAP and
RTX in nonarthritic mice had no effect on expression of SP in the DRG.
Conclusions: Using ADWB and EPS, we were able to quantitate pain in a
murine chronic inﬂammatory arthritis model. Chronic inﬂammatory
arthritis pain produced a signiﬁcant increase in EPS and decreased ADWB
measures in the affected limb. Treatment with RTX in these mice resulted
inanon statistically signiﬁcant improvement inpainmeasures as assessed
Fig1B. 6 months follow-up radiograph depicts deﬁnite medial joint space
narrowing (JSN; arrows) with persistent absence of osteophytes medially
consistent with RPOA.
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different than those found in mice with acute inﬂammatory arthritis that
were pretreatedwith vanilloids. SP expression in theDRG of arthriticmice
was increased compared to naïve but IA treatment with CAP normalized
this expression. The use IA RTX or CAP for analgesia in chronic inﬂam-
matory arthritis will require additional consideration of optimal dose and
timing of administration which has yet to be determined.
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RELEVANCE OF IMAGING IN ANTI NERVE GROWTH FACTOR
INHIBITOR (ANGF) STUDIES WITH A FOCUS ON ELIGIBILITY AND
ON-STUDY SAFETY e A PICTORIAL OVERVIEW
F.W. Roemer y, C. Miller z, K. Hoover x, C. Hayes k, C. West ¶, M. Brown ¶,
R. Clemmer ¶, A. Guermazi y. yBoston Univ. Sch. of Med., Boston, MA, USA;
zBioClinica, Princeton, NJ, USA; xVirginia Commonwealth Univ., Richmond,
VA, USA; kVirginia Commonwealth Univ., Richmond, PA, USA; ¶ Pﬁzer,
Groton, CT, USA
Purpose: Monoclonal antibodies that bind and inhibit nerve growth
factor (NGF) have demonstrated both good analgesic efﬁcacy and
improvement in function in patients with osteoarthritis (OA). Anti-(a)
NGF therapies offer potential as the ﬁrst new class of analgesics for
many years. Despite promising efﬁcacy data, trials in OA were sus-
pended due to concerns over accelerated rates of OA progression inFig 1A. Baseline radiograph shows a normal medial and lateral joint space
width.some patients. However, continued development of aNGF drugs with
rigorous safety screening criteria in future trials is planned and imaging
will play a crucial role. Imaging will be used to deﬁne the eligibility of
potential participants and to monitor safety during the course of these
studies in order to identify subjects at risk for rapidly progressive OA
(RPOA) prior to inclusion or to withdraw subjects from treatment early
due to the occurrence of joint safety events such as RPOA.
The aim of this presentation is to describe and illustrate MRI and
radiographic imaging ﬁndings that will be important for patient eligi-
bility and safety monitoring in planned studies of aNGF compounds.
Methods: This illustrative presentation is based on repetitive meetings
of four experienced musculoskeletal radiologists to deﬁne potentialFig 2. Coronal T1 weighted MR image shows typical metaphyseal osteo-
necrosis (arrows) with central fat-like signal (asterisk).
